Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 USD | -7.09% | -18.06% | -21.33% |
Apr. 09 | Transcript : Immunic, Inc. - Special Call | |
Mar. 21 | Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium | MT |
Business Summary
Number of employees: 77
Managers
Managers | Title | Age | Since |
---|---|---|---|
Daniel Vitt
CEO | Chief Executive Officer | 55 | 16-12-31 |
Glenn Whaley
DFI | Director of Finance/CFO | 56 | 19-11-30 |
Hella Kohlhof
CTO | Chief Tech/Sci/R&D Officer | 51 | 16-12-31 |
Andreas Muehler
CTO | Chief Tech/Sci/R&D Officer | 60 | 16-07-31 |
Jessica Breu
IRC | Investor Relations Contact | - | - |
Patrick Walsh
PRN | Corporate Officer/Principal | 41 | 21-10-13 |
Inderpal Singh
LAW | General Counsel | 58 | 21-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Barclay Phillips
BRD | Director/Board Member | 61 | 19-11-18 |
Tamar Howson
BRD | Director/Board Member | 75 | 19-10-10 |
Jörg Neermann
BRD | Director/Board Member | 57 | 19-03-31 |
Daniel Vitt
CEO | Chief Executive Officer | 55 | 16-12-31 |
Duane Nash
CHM | Chairman | 53 | 18-12-31 |
Richard Rudick
BRD | Director/Board Member | 73 | 23-04-25 |
Monika Tornsen
BRD | Director/Board Member | 45 | 22-07-04 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 89,929,016 | 82,989,362 ( 92.28 %) | 0 | 92.28 % |
Company contact information
Immunic, Inc.
1200 Avenue of the Americas Suite 200
10036, New York
+
http://www.immunic-therapeutics.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.33% | 106M | |
-3.10% | 102B | |
+2.11% | 96.37B | |
-1.80% | 21.37B | |
-17.75% | 20.92B | |
-6.91% | 18.64B | |
-42.00% | 16.4B | |
-28.19% | 13.53B | |
+0.18% | 13.28B | |
+19.90% | 10.85B |
- Stock Market
- Equities
- IMUX Stock
- Company Immunic, Inc.